ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1271

Linkage of the Childhood Arthritis and Rheumatology Research Alliance Registry with the Pediatric Health Information System: Creation of a Comprehensive Childhood-Onset Lupus Dataset

Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1240

Living with Antiphospholipid Antibodies: A Photovoice Exploration

Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1312

Long Term Proficiency and Clinical Outcomes of a Novel Fellow’s Injection Clinic

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1345

Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1120

Long-Term Echocardiographic Findings in Idiopathic Recurrent Pericarditis Patients Treated with Anakinra

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1104

Long-term Follow-up of Patients with Positive Cryofibrinogen Test During the COVID-19 Era

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1246

Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies

Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1094

Longitudinal Analysis of Serum Urate in Prediabetic Phase

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1227

Longitudinal Patterns of Fibromyalgia Phenotypes in Patients with Systemic Lupus Erythematosus

Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1396

Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis

RA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1607

Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 1511

Lupus Nephritis and Response to Treatment in Latin America

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1489

Lupus Nephritis Clinical and Serological Responses at 12 Months: Implications for Repeat Biopsy, Intensified Immunosuppression or Additional Anti-proteinuric Therapy

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1129

Machine Learning Algorithms to Predict Colchicine Resistance in Familial Mediterranean Fever

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1364

Machine Learning-Driven Models for Disease Activity Prediction and Therapeutic Response Evaluation in Rheumatoid Arthritis Patients: An Analysis of Data from the Multicentre, Prospective, Egyptian Collage of Rheumatology (ECR) Study Group

RA – Diagnosis, Manifestations, & Outcomes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].